ArticleCancer medicine2026

Target-Specific Dermatological Adverse Event Reporting With T-Cell-Engaging Bispecific Antibodies: A Pharmacovigilance Analysis of FAERS and Canada Vigilance, 2016-2026.

Saikat Mandal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.